See the DrugPatentWatch profile for Crenessity
Is Crenessity (Neurocrine) FDA-approved as of 2026?
Based on the information provided, there is not enough data to verify Crenessity’s (Neurocrine’s) FDA approval status in 2026. I can’t reliably confirm whether it has FDA approval, the approval date, or whether it is still under review.
What FDA approval should you look for in 2026 (and where to check)?
If you’re trying to confirm an approval, the most direct places to check are:
- FDA Drugs@FDA (lists approvals by product name, active ingredient, and approval date)
- FDA press releases and approval letters (for the specific application and indication)
- Neurocrine’s investor/press materials (they often announce approvals for each product and indication)
Could “Crenessity” be a misspelling, nickname, or not-the-final product name?
It’s also possible the term you’re using does not match the FDA-approved product name. Companies and early pipeline materials sometimes use brand-like names or working names that later change. Verifying the exact FDA-tracked name (or the generic/active ingredient) is usually necessary to confirm status.
If it’s not approved yet, what stage might it be in?
If it is not yet approved, typical FDA pathways include:
- Active clinical trials
- Submission of a New Drug Application (NDA) or Biologics License Application (BLA)
- FDA review (PDUFA date/response cycle) or an FDA Complete Response Letter
The exact stage depends on the application and product identifier.
What I need from you to answer accurately
Send one of the following and I can pinpoint the 2026 status precisely:
- The exact spelling of the product name as shown on the source you saw
- The active ingredient / generic name
- The FDA application type (NDA/BLA) or a link/screenshot to where “Crenessity” is mentioned
Sources
No sources were provided, and none could be used to verify “Crenessity” FDA approval status in 2026.